Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Design
The MarketWatch News Department was not involved in the creation of this content. Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a...
The MarketWatch News Department was not involved in the creation of this content. Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a...
